January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Dr. Jianyong Shou, CSO, Founder at EnnovaBio, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
2026 年 1 月 11 日（旧金山洲际酒店）——我们很高兴地宣布，轶诺药业创始人兼研发总裁 寿建勇 博士将在 ACCESS ASIA 药通亚洲 BD 论坛 @ JPM 2026 上发表演讲。
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
由雅法主办的”ACCESS ASIA”论坛，延续ACCESS CHINA的成功经验，将亚洲领先的生物科技跨境平台拓展至更广阔领域，连接创新者与全球药企、投资机构和战略合作伙伴。论坛将于2026年1月11日在旧金山洲际酒店举行，为亚洲生物科技企业提供全球舞台，展示创新成果，促成战略合作，开拓商业发展新机遇。更多信息请访问：https://biotochina.org/
About EnnovaBio
Shanghai EnnovaBio Pharmaceuticals Co., Ltd. is a clinical-stage biotech company led by a group of seasoned drug discovery and development scientists, focusing on delivering first-in-class treatments for inflammation and metabolic complications with key differentiations. Powered by systems biology-guided disease characterization and target discovery with cutting-edge computational technologies, EnnovaBio has built an innovative drug discovery and development pipeline. Currently, multiple projects, including EnnovaBio’s proprietary first-in-class oral small-molecule therapy for diabetic macular edema (DME) and cardiac surgery-associated acute kidney injury (CSA-AKI) have advanced into Phase II clinical development with promising therapeutic potential indicated.
上海轶诺药业有限公司是一家临床阶段的新药研发公司，由多位资深药物专家领衔，致力于自身免疫、慢性炎症及代谢并发症等重大复杂疾病领域的“国际首创”药物研发。公司通过整合系统生物学和深度学习人工智能技术，实现对新药研发全链条的指导，搭建了一体化的新药研发平台，建立了具有国际竞争力的首创新药管线。目前，公司自主研发多个项目包括国际首创的口服治疗糖尿病眼病，以及针对心脏手术相关急性肾损伤的药物均在开展II期临床研究，并逐步显示出治疗潜力。
演讲嘉宾
About the speaker
寿建勇 博士 Dr. Jianyong Shou
CSO, Founder
EnnovaBio
Dr. Shou is the Founder and Chief Scientific Officer of Shanghai EnnovaBio Pharmaceuticals. As a seasoned expert in drug discovery and development, he has held several key leadership roles at globally renowned pharmaceutical companies. His experience includes establishing and leading the Regenerative Medicine Department at Novartis China; serving as Biology Head and Director of Neuroinflammation BU at GSK China; and working as Head and Senior Director of the Biology Department at Lilly China R&D Center. Dr. Shou has achieved multiple internationally recognized original breakthroughs across oncology, stem cells and regenerative medicine, metabolism, neuroscience, and other therapeutic areas. He has led and contributed to more than 10 innovative drug programs and multiple cutting-edge drug discovery platforms. Dr. Shou has published nearly 40 papers in top-tier journals such as Nature Neuroscience, Nature Communications, Genome Research, PNAS, and JCI. He is also an invited reviewer for several leading journals, including Science.
寿博士现任上海轶诺药业有限公司创始人兼研发总裁，是一位资深药物研发专家。他曾在多家国际知名制药企业担任关键领导职位，包括创建并领导诺华中国再生医学部门；担任 GSK 神经免疫生物部门负责人、总监；以及礼来中国研发中心生物部负责人、高级总监。在肿瘤、干细胞与再生医学、代谢、神经等多个疾病领域，寿博士取得了多项国际领先的原创性成果，领导参与了10余个 1.1 类新药项目及多个创新药物研发平台的建设。寿博士在 Nature Neuroscience、Nature Communications、Genome Research、PNAS、JCI 等国际顶级期刊发表论文近40篇，并受邀担任 Science 等多份权威期刊的特约审稿人。
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
Contact Us
Register as an attendee for ACCESS ASIA BD Forum @ JPM:
For more information, please contact:
Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 